Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis

INTRODUCTION: Ensifentrine is an inhaled first-in-class dual inhibitor of phosphodiesterase (PDE) 3 and 4. In a four-week randomized, double-blind, placebo-controlled, parallel-group study in patients with chronic obstructive pulmonary disease (COPD), nebulized ensifentrine 0.75 to 6mg twice daily s...

Descripción completa

Detalles Bibliográficos
Autores principales: Watz, Henrik, Rickard, Kathleen, Rheault, Tara, Bengtsson, Thomas, Singh, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502392/
https://www.ncbi.nlm.nih.gov/pubmed/32982212
http://dx.doi.org/10.2147/COPD.S263025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502392/
https://www.ncbi.nlm.nih.gov/pubmed/32982212
http://dx.doi.org/10.2147/COPD.S263025

Ejemplares similares